Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder

Summary

Psychedelic therapies, especially MDMA-assisted therapy, show promise for treating PTSD by targeting underlying causes rather than just symptoms. A review of studies found that MDMA-assisted therapy led to 67% of participants no longer meeting PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression, while ketamine offers rapid symptom relief for treatment-resistant cases with high risk of self-harm. These treatments work by inducing neuroplasticity and augmenting fear extinction through specific biological pathways. Despite regulatory challenges, standardized protocols are needed to ensure safety and reproducibility in future research.

Study at a glance

Abstract

Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging psychedelic therapies in the management of PTSD, with a primary focus on 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine. Material and methods. A literature search was carried out using PubMed, Google Scholar, and Scopus to identify relevant studies using keywords such as 'PTSD', 'MDMA', 'psychedelics', 'ketamine', 'psychedelic-assisted therapy', 'neuroplasticity', and 'fear extinction'. Results. Psychedelics induce neuroplasticity and augment fear extinction, primarily through the AMPAR-BDNF-TrkB-mTOR pathway and 5-HT2A receptors. MDMA-assisted therapy demonstrates high efficacy, with a trial showing that 67% of participants no longer met PTSD criteria at the study endpoint. Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression. Ketamine offers rapid symptom alleviation, making it notably beneficial for treatment-resistant cases with a high risk of self-harm and suicide. Conclusions. Psychedelic therapies, particularly MDMA-assisted therapy, represent a potential breakthrough by targeting the underlying causes of PTSD rather than merely suppressing symptoms. In spite of current regulatory problems, they hold meaningful promise, pointing out the need for standardized treatment protocols to ensure safety and reproducibility in future research.